This is an aggregated industry headline. Read the full story at FierceBiotech →
AstraZeneca pens $2.1B Sino deal for challenger to Merck's COPD drug Ohtuvayre
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.'s chronic obstructive pulmonary disease drug Ohtuvayre.
By FierceBiotech
· Jul 8, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees…
The WeekBriefing
Vertex’s Casgevy can now treat sickle cell disease and transfusion-dependent beta thalassemia in patients aged…
The WeekSTAT News ↗
The White House has proposed sweeping changes to the bedrock regulation undergirding all federal contracts, em…